The webinar covers the following points:
- The importance of integrating multi-omics at a systemic level to generate key biological insights for cancer prevention, diagnosis, and treatment
- Emerging large-scale cancer proteomics analyses at the population level
- Using high-throughput proteomics to find actionable biomarkers to better understand and treat human cancer.
Original Broadcast date: November 23 2021
Dr. Mälarstig received his Ph.D. in cardiovascular genetics from Uppsala University in 2006 and then did postdoctoral training at the Karolinska Institute in Stockholm. In 2009 he joined Pfizer, where he is now director of Target Sciences. In his current role, he is responsible for developing and applying strategies for new drug targets and precision medicine. He has extensive experience working in international academic consortia and public-private partnerships such as the SCALLOP consortium, which recently published their first article in Nature Metabolism, entitled “Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals.”